Table 2.
Demographic and clinical characteristics of participants.
| Author (year); country of origin | Study design | Sample size; (male/female) | Age (y) | MGFA classification | Flare (F)/New-onset(N) | Treatments before vaccination | Type of vaccine used |
|---|---|---|---|---|---|---|---|
| Dharmasaroja (2022); Thailand (19) | CR | N=1; (0/1) | 31 | IIa | 1 F | Prednisolone 15 mg 1/2d, pyridostigmine 120 mg 3/d | BNT162b2 |
| Fanella et al. (2022); Italy(20) | CS | N=3; (3/0) | 91/80/55 | NR | 3 N | / | BNT162b2, mRNA-1273 |
| Galassi et al. (2022); Italy(21) | CR | N=1; (1/0) | 73 | NR | 1 N | / | ChAdOx1 nCoV-19 |
| Huang et al. (2022); China(22) | CR | N=1; (1/0) | 53 | NR | 1 N | / | ChAdOx1 nCoV-19 |
| Kang et al. (2022); South Korea(23) |
CR | N=1; (1/0) | 35 | NR | 1 N | / | ChAdOx1 nCoV-19 |
| Lee et al. (2022); South Korea(24) |
CR | N=1; (1/0) | 32 | NR | 1 N | / | BNT162b2 |
| Sonigra et al. (2022); KEN(25) | CR | N=1; (1/0) | 55 | NR | 1 F, MC | Prednisone 15 mg 1/2d, pyridostigmine 60 mg 1/d, AZA 150 mg 1/d | ChAdOx1 nCoV-19 |
| Slavin et al. (2022); USA(26) | CR | N=1; (1/0) | 60 | NR | 1 N | / | mRNA-1273 |
| Abicic et al. (2022); HRV(27) | CR | N=1; (1/0) | 65 | NR | 1 N | / | BNT162b2 |
| Hoshina et al. (2022); Japan(28) | CR | N=1; (1/0) | 30 | NR | 1 N | / | mRNA-1273 |
| Maher et al. (2022); Australia (29) | CR | N=1; (1/0) | 52 | NR | 1 N | / | ChAdOx1 nCoV-19 |
| Poli et al. (2022); Germany (30) | CR | N=1; (1/0) | 65 | NR | 1 N | / | BNT162b2 |
| Ramdas et al. (2022); UK(31) | CS | N=7; (5/2) | Median age at diagnosis: 63 | NR | 7 N | / | BNT162b2, ChAdOx1 nCoV-19 |
| Chavez et al. (2021); USA(32) | CR | N=1; (1/0) | 82 | NR | 1 N | / | BNT162b2 |
| Croitoru et al. (2022); Romania (33) | CR | N=1; (1/0) | 78 | IIb | 1 N, MC | / | BNT162b2 |
| Watad et al. (2021); UK(34) | CS | N=2; (2/0) | 72/73 | NR | 2 N | / | BNT162b2 |
| Tagliaferri et al. (2021); USA (35) | CR | N=1; (1/0) | 77 | NR | 1 F, MC | Prednisone 7.5 mg 1/d, pyridostigmine 60 mg 6/d | mRNA-1273 |
| Ruan et al. (2021); China(36) | CS | N=22; (16/6) | Mean onset age: 45.4 | 3 I, 1 IIb, 18 asymptomatic | 2 F | 12 AZA, 2 mycophenolate mofetil, 3 steroids combined with AZA | inactivated vaccines, recombinant subunit vaccines |
| Doron et al. (2022); Israel(37) | Cross-sectional study | N=160; (89/71) | 57.2 ± 18 | NR | 9 F, 4 N | NR | BNT162b2 |
| Farina et al. (2022); Italy(38) | Retrospective cohort study | N=104; (55/49) | Mean onset age: 57 | 21 I, 12 IIa, 19 IIb, 12 IIIa, 22 IIIb, 1 IVa, 8 IVb, 9 V | 8F | 69 corticosteroids, 21 AZA, 15 mycophenolate, 4 IVIG, 3 rituximab, 2 cyclosporine A | BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 |
| Ishizuchi et al. (2022); Japan(39) | Prospective cohort study | N=343; (119/224) | 57 | 73 I, 128 II, 108 III, 10 IV, 24 V | 3 F | 240 prednisolone, 121 tacrolimus,26 cyclosporine, 93 IVIG, 102 methylprednisolone pulse therapy, 50 PE, 6 anti-complement |
BNT162b2, mRNA-1273 |
| Urra Pincheira et al. (2022); Canada (11) | Retrospective chart review | N=200; (103/97) | 64.3 ± 13.9 | NR | / | 73 only pyridostigmine, 56 IVIG/PE, 91 one immunosuppressant agent, 30 two immunosuppressant agents, 7 three immunosuppressant agents | BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 |
| Sansone and Bonifati (2022); Italy(16) | Retrospective cohort study | N=80; (41/39) | 60.4 | NR | 4 F | NR | BNT162b2, Mrna-1273, ChAdOx1 nCoV-19 |
| Reyes-Leiva et al. (2022); Spain (40) | Prospective cohort study | N=100; (45/55) | Mean onset age: 55.85 | 52 asymptomatic, 13 I, 33 IIa, 2 IIIa | 1 F | 9 cholinesterase inhibitor monotherapy, 67 prednisone, 14 AZA, 21 mycophenolate mofetil, 6 cyclosporine, 7 tacrolimus, 9 rituximab, 3 IVIG, 1 PE | mRNA-1273 |
| Lupica et al. (2022); Italy(41) | Retrospective cohort study | N= 53; (29/24) | 63 | NR | 14 F | NR | BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 |
| Gamez et al. (2022); Spain(42) | Prospective cohort study | N=91; (36/55) | Mean onset age: 44.41 ± 20.97 | 13 I, 38 II, 29 III, 11 IV | 2 F | 42 pyridostigmine, 28 prednisone, 5 AZA, 5 mycophenolate, 58 tacrolimus, 9 IVIG | mRNA-1273, BNT162b2 |
| Li et al. (2022); China(43) | Retrospective survey-base study | N=107; (54/53) | 45.68 ± 1.49 | 41 asymptomatic, 29 I, 30 IIa, 6 IIb, 1 IIIa | 11 F | NR | homologous inactivated vaccines, homologous recombinant subunit vaccines |
| Lotan et al. (2022); Israel(44) | Retrospective survey-base study | N=56; (35/21) | 53 | NR | 8 F | 28 corticosteroids 28, 4 AZA, 3 mycophenolate mofetil, 2 methotrexate, 9 rituximab, 6 IVIG, 2 PE, 1 eculizumab | BNT162b2 |
| Mirmosayyeb et al.(2022); Iran (45) | Systematic review | N=5; (4/1) | 66.6 | NR | 5 N | / | BNT162b2, ChAdOx1 nCoV-19 |
MGFA, Myasthenia Gravis Foundation of America; CR, case report; NR, not reported; MC, myasthenia crisis; AZA, azathioprine; IVIG, intravenous immunoglobulin; PE, plasma exchange.